Lise Barlebo Ahlborn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lise Barlebo Ahlborn has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Christina S.A. Andersen
22 shared publications- Julie Gehl
Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark
22 shared publications - Malene Støchkel Frank
Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
22 shared publications - Niels Pallisgaard
Department of Pathology, Zealand University Hospital, Roskilde, Denmark
22 shared publications - Uffe Bodtger
Respiratory Research Unit PLUZ, Department of Internal and Respiratory Medicine, Zealand University Hospital, 4700 Næstved, Denmark
22 shared publications Ane Y. Steffensen
University of Copenhagen
3 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers
We report a patient with a pathogenic germline variant (PGV) in RB1 and somatic mosaicism for a pathogenic TP53 variant who developed three distinct types of childhood cancer: retinoblastoma, osteosarcoma, and myelodysplastic syndrome (MDS) before the age of 6 years. The patient presented with bilateral retinoblastoma at age 4 weeks and a PGV in RB1 was found. At the very young age of 3 years, she developed an osteosarcoma. A pathogenic variant in TP53 was initially found in bone marrow as part of the diagnostic workup for the patient's third cancer, MDS rapidly progressing to acute myeloid leukemia (AML). Due to the unusual clinical phenotype, cultured fibroblasts from a skin biopsy were examined and identified somatic TP53 mosaicism, with a VAF of 7%. The early debut of osteosarcoma at age 3 years indicates a stronger predisposition than only heritable retinoblastoma would explain, but the development of subsequent MDS could implicate a vulnerability to chemotherapy due to digenic cancer predisposition. This unusual clinical course underlines the need for a better understanding of genetic predisposition to cancer and the interplay between genetic predisposition and treatment effects in optimizing therapeutic strategies and improving long‐term outcomes for these patients.
- 8 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Open AccessConcurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers
We report a patient with a pathogenic germline variant (PGV) in RB1 and somatic mosaicism for a pathogenic TP53 variant who developed three distinct types of childhood cancer: retinoblastoma, osteosarcoma, and myelodysplastic syndrome (MDS) before the age of 6 years. The patient presented with bilateral retinoblastoma at age 4 weeks and a PGV in RB1 was found. At the very young age of 3 years, she developed an osteosarcoma. A pathogenic variant in TP53 was initially found in bone marrow as part of the diagnostic workup for the patient's third cancer, MDS rapidly progressing to acute myeloid leukemia (AML). Due to the unusual clinical phenotype, cultured fibroblasts from a skin biopsy were examined and identified somatic TP53 mosaicism, with a VAF of 7%. The early debut of osteosarcoma at age 3 years indicates a stronger predisposition than only heritable retinoblastoma would explain, but the development of subsequent MDS could implicate a vulnerability to chemotherapy due to digenic cancer predisposition. This unusual clinical course underlines the need for a better understanding of genetic predisposition to cancer and the interplay between genetic predisposition and treatment effects in optimizing therapeutic strategies and improving long‐term outcomes for these patients.
- 20 April 2026
- Published by Elsevier in Cancer Genetics
- Vol. 304-305, 160-164
Novel truncating WT1 germline variant in a case of familial Wilms tumor
- 20 April 2026
- Published by Elsevier in Cancer Genetics
- Vol. 304-305, 160-164
Novel truncating WT1 germline variant in a case of familial Wilms tumor
- Open Access
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400266
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors
PURPOSE: It is a clinical challenge to select patients for BRAF-targeted therapy because of the lack of predictive biomarkers besides the BRAF V600E mutation. By analyzing the genome, transcriptome, and proteome, this study investigated the association between baseline molecular alterations and outcomes of BRAF-targeted therapy. PATIENTS AND METHODS: Fresh tumor tissue from patients enrolled in the Copenhagen Prospective Personalized Oncology study was collected and underwent comprehensive molecular profiling. RESULTS: TP53 comutations were most frequently detected. Patients with a TP53 wild-type tumor had a significantly longer median progression-free survival than those with TP53 comutations (hazard ratio, 2.8 [95% CI, 1.13 to 7.08]; P = .02). RNAseq revealed a distinct gene expression signature for patients with long-term disease control (LDC), including hallmarks of cell cycle arrest and proliferation in the p53 pathway. The protein analysis demonstrated that ubiquitin-conjugating enzyme EK2 was significantly downregulated in patients with LDC. CONCLUSION: Using a multiomic approach, we identified molecular alterations associated with treatment outcomes. The potential of analyzing multiomic data is promising and should be prioritized in translational cancer research to uncover the full potential within precision oncology.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400266
Open AccessMultiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors
PURPOSE: It is a clinical challenge to select patients for BRAF-targeted therapy because of the lack of predictive biomarkers besides the BRAF V600E mutation. By analyzing the genome, transcriptome, and proteome, this study investigated the association between baseline molecular alterations and outcomes of BRAF-targeted therapy. PATIENTS AND METHODS: Fresh tumor tissue from patients enrolled in the Copenhagen Prospective Personalized Oncology study was collected and underwent comprehensive molecular profiling. RESULTS: TP53 comutations were most frequently detected. Patients with a TP53 wild-type tumor had a significantly longer median progression-free survival than those with TP53 comutations (hazard ratio, 2.8 [95% CI, 1.13 to 7.08]; P = .02). RNAseq revealed a distinct gene expression signature for patients with long-term disease control (LDC), including hallmarks of cell cycle arrest and proliferation in the p53 pathway. The protein analysis demonstrated that ubiquitin-conjugating enzyme EK2 was significantly downregulated in patients with LDC. CONCLUSION: Using a multiomic approach, we identified molecular alterations associated with treatment outcomes. The potential of analyzing multiomic data is promising and should be prioritized in translational cancer research to uncover the full potential within precision oncology.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure FS3 from Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
OS and PFS – above/below median
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure FS3 from Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
OS and PFS – above/below median
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table TS1 from Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
Sequencing data of tumor tissue in each patient case
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table TS1 from Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
Sequencing data of tumor tissue in each patient case